Analysts Impressed As Novo Nordisk’s PIONEER 6 Trial Confirms Safety Profile Of Oral Semaglutide

 
• By Sten Stovall
  
Heart
Trial is part of Novo Nordisk's PIONEER clinical development program • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas